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1	Introduction





arthritis	model	showed	mice	genetically	deficient	 in	 the	DR3	gene	 (DR3ko)	as	presenting	with	reduced	pathology	and	 inflammatory	cell	 infiltrate	 [6,19].	This	has	been	attributed	 to	multiple	DR3-driven	 functions	which	 impact	on
effector	T	cell	development,	osteoclast	differentiation	[20]	and	cytokine/chemokine	release.	TNFSF15	has	also	been	implicated	in	other	bone	disorders	such	as	ankylosing	spondylitis	[21,22]	and	IBD	development	[23].	TL1A	levels	were
























































































Chemokine DR3wt DR3ko Significance$
PBS* OVA^ PBS* OVA^
Acute CCL3 N/A† N/A† N/A† N/A† N/A†
CCL4 N/A† N/A† N/A† N/A† N/A†
CCL5 74	±	18 92	±	10 77	±	15 78	±	18 p	=	0.55	N.S.D
CXCL1 N/A† N/A† N/A† N/A† N/A†
CXCL2 90	±	21 107	±	7 144	±	55 85	±	18 p	=	0.41	N.S.D
CXCL10 310	±	36 342	±	26 359	±	72 275	±	33 p	=	0.15	N.S.D
CXCL13 229	±	34 275	±	51 456	±	180 292	±	39 p	=	0.79	N.S.D
Chronic CCL3 36	±	10 31	±	5 38	±	4 27	±	3 p	=	0.46	N.S.D




CCL5 145	±	40 125	±	22 138	±	21 96	±	11 p	=	0.26	N.S.D
CXCL1 74	±	16 45	±	6 63	±	5 48	±	8 p	=	0.79	N.S.D
CXCL2 254	±	54 216	±	20 272	±	18 185	±	25 p	=	0.35	N.S.D
CXCL10 799	±	144 955	±	246 941	±	90 666	±	64 p	=	0.28	N.S.D


































was	 concurrent	 with	 DR3	 up-regulation	 in	 the	 lung.	 Interestingly	 however,	 during	 the	 chronic	 phase	 of	 disease,	 DR3	 promoted	 airway	 remodelling	 via	 goblet	 cell	 hyperplasia	 and	 immuno-pathology,	 including	 bronchiole	 and
parenchyma	cell	infiltration.















antibody	production	(data	not	shown)	were	not	DR3	dependent.	This	 is	 further	supported	by	the	 lack	of	differences	noted	 in	chemokine	concentrations,	which	were	previously	 identified	as	DR3	dependent	during	acute	peritoneal
fibrosis	[37]	but	not	after	viral	challenge	[2].	Moreover,	none	of	the	BALF	cell	subsets	studied	differed	significantly	between	DR3wt	and	DR3ko	mice	following	multiple	OVA	aerosolisation	challenges.	This	is	a	common	occurrence	when
modelling	chronic	allergic	lung	protocols,	which	continue	to	be	problematic	in	exhibiting	all	the	characteristics	of	human	asthma	[46].	Koerner-Rettberg	et	al.	noted	sustained	airway	lymphocytosis	but	short	lived	eosinophilia	upon	long







Whilst	 chronic	models	 of	 allergic	 lung	 disease	 have	 been	 shown	 to	 have	modest	 levels	 of	 infiltration,	 airway	 remodelling	 is	 considered	 a	 fundamental	 feature	 of	 the	 disease.	 Intriguingly,	 despite	 flow	 cytometry	 results
suggesting	few	differences	 in	BALF	leukocyte	accumulation,	H&E	stained	lung	tissue	showed	greater	cellular	 infiltration	in	the	peribronchial	and	perivascular	areas	of	DR3wt	OVA	challenged	mice,	 implying	DR3	is	 involved	in	the







asthma	and	via	the	production	of	mucus	plugs,	also	to	 fatalities	 [49,56].	DR3	has	already	been	shown	to	have	a	role	 in	goblet	cell	hyperplasia,	albeit	 in	a	model	of	small	 intestinal	 inflammation	[26–28].	Mice	which	constitutively
expressed	TL1A	on	both	T	cells	[27]	and	DCs	[28]	spontaneously	developed	small	bowel	disease	which	was	characterised	by	goblet	cell	hypertrophy	and	hyperplasia,	thought	to	be	IL-13	driven.	More	recently,	Moltke	et	al.	suggest
small	intestine	epithelial	tuft	cell	derived	signals	to	be	the	key	activators	of	ILC2s	and	thereby	IL-13	and	goblet	cell	hyperplasia	[57],	suggesting	perhaps	TL1A	could	be	released	by	tuft	cells	and	activate	ILC2s	in	this	manner.




and	 IL-13	 release	 [60].	 Similarly,	 TNFR	 p55/p75	 deficient	mice	 demonstrated	 significantly	 reduced	 peribronchial	 fibrosis,	 smooth	muscle	 layer	 and	 deposition	 of	 extracellular	matrix	 proteins	 in	 a	model	 of	 chronic	 allergic	 lung
inflammation	[61].	The	lack	of	differences	shown	here	suggests	that	amongst	the	TNFRSF,	DR3	is	not	essential	for	the	initiation	and	development	of	lung	fibrosis.
The	relationship	between	airway	inflammation	and	airway	remodelling	is	poorly	understood.	This	is	made	more	difficult	by	the	variety	of	sensitisation	and	challenge	protocols	used	as	well	as	the	array	of	read-outs	used	to
assess	the	responses.	Data	here	corroborates	published	literature	stating	that	loss	of	DR3	function	ameliorates	acute	allergic	lung	inflammation,	shown	by	reduced	cellular	infiltration	into	the	BALF.	In	a	more	clinically	relevant	model
of	chronic	allergic	lung	inflammation,	DR3ko	OVA	mice	exhibited	lower	mucin	levels	and	inflammation	in	the	lung	parenchyma	compared	to	DR3wt	mice,	although	the	underlying	mechanisms	behind	this	are	unknown.	This	is	the	first
report	of	DR3	in	chronic	allergic	lung	inflammation	and	its	potential	as	a	therapeutic	target	for	antagonism	of	goblet	cell	hyperplasia	and	associated	mucus	over-production	as	a	result	of	allergic	disease.Acknowledgments
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Highlights
• DR3	has	distinctive	roles	in	acute	and	chronic	stages	of	allergic	lung	inflammation.
• In	acute	lung	inflammation,	DR3ko	mice	are	protected	from	lung	cell	infiltration.
• In	chronic	lung	disease,	DR3	is	essential	for	goblet	cell	hyperplasia.
• Conclude	that	DR3	may	be	required	for	the	development	of	lung	pathology.
